Video Experimental Relacionado
Updated: Feb 21, 2026
14:55
Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
Published on: May 12, 2013
62.0K
Osilodrostat para el tratamiento del síndrome de Cushing: una actualización
Lukasz Dzialach1, Przemyslaw Witek1
1Department of Internal Medicine, Endocrinology and Diabetes, Medical University of Warsaw, Warsaw, Poland.
Expert review of endocrinology & metabolism
|February 20, 2026
Resumen
El osilodrostat reduce efectivamente el cortisol en el síndrome de Cushing (SC), mejorando los resultados de los pacientes. Esta revisión cubre su eficacia, seguridad y manejo práctico, destacando su valor en el tratamiento de este complejo trastorno endocrino.
Área de la Ciencia:
- Endocrinología Endocrinología.
- Farmacología Farmacología.
Sus antecedentes:
- El síndrome de Cushing (SC) presenta complejos desafíos endocrinos con un difícil manejo a largo plazo.
- El osilodrostato, un inhibidor de la 11β-hidroxilasa, ofrece una nueva vía terapéutica.
Objetivo del estudio:
- Revisar los datos clínicos y del mundo real sobre la eficacia y seguridad de osilodrostat en CS.
- Proporcionar orientación práctica sobre el uso de osilodrostat, incluida la dosificación y el manejo de eventos adversos.
Principales métodos:
- Revisión de las pruebas clínicas actuales.
- Análisis de datos del mundo real sobre el osilodrostato en el hipercortisolismo endógeno.
Principales resultados:
- Osilodrostat demuestra una reducción significativa del cortisol y mejora la salud metabólica, cardiovascular y psicológica.
- Es bien tolerado y efectivo en diversas formas y severidades de CS.
Conclusiones:
- El osilodrostat es un tratamiento valioso y eficaz para el síndrome de Cushing.
- La evidencia del mundo real apoya su utilidad en el manejo del hipercortisolismo endógeno.
Videos de Conceptos Relacionados
01:21Drugs for Treatment of Constipation-Predominant IBS
926
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
926
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
546
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
546
01:21Drug Dosing: Obese Patients
298
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
298
01:26COPD: Management Using Bronchodilators and Corticosteroids
888
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
888
01:17Drugs for Treatment of Diarrhea-Predominant IBS
767
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
767
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.3K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.3K